Full-year forecasts and an ambitious target to almost double group revenues by 2030 remain intact at AstraZeneca despite “mixed” first-quarter results and the prospect of import tariffs in the United States, its largest market. Total revenue rose 10 per cent to $13.6 billion in the first three months of the year, propelled by double-digit growth in cancer medicines and biopharmaceuticals and growth across all its major geographic regions. However, it was behind the consensus forecast of analysts for $13.8 billion and weighed on AstraZeneca’s share price, which traded down more than 5 per cent before recovering to close up 92p, or 0.9 per cent, on the day at £106.18 on the London Stock Exchange. Sir Pascal Soriot, AstraZeneca’s long-serving chief executive, said the record revenues
